Genetic insight into Birt-Hogg-Dubé syndrome in Indian patients reveals novel mutations at FLCN
© 2022. The Author(s)..
BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is a rare monogenic condition mostly associated with germline mutations at FLCN. It is characterized by either one or more manifestations of primary spontaneous pneumothorax (PSP), skin fibrofolliculomas and renal carcinoma (chromophobe). Here, we comprehensively studied the mutational background of 31 clinically diagnosed BHDS patients and their 74 asymptomatic related members from 15 Indian families.
RESULTS: Targeted amplicon next-generation sequencing (NGS) and Sanger sequencing of FLCN in patients and asymptomatic members revealed a total of 76 variants. Among these variants, six different types of pathogenic FLCN mutations were detected in 26 patients and some asymptomatic family members. Two of the variants were novel mutations: an 11-nucleotide deletion (c.1150_1160delGTCCAGTCAGC) and a splice acceptor mutation (c.1301-1G > A). Two variants were Clinvar reported pathogenic mutations: a stop-gain (c.634C > T) and a 4-nucleotide duplication (c.1329_1332dupAGCC). Two known variants were: hotspot deletion (c.1285delC) and a splice donor mutation (c.1300 + 1G > A). FLCN mutations could not be detected in patients and asymptomatic members from 5 families. All these mutations greatly affected the protein stability and FLCN-FNIP2 interaction as observed by molecular docking method. Family-based association study inferred pathogenic FLCN mutations are significantly associated with BHDS.
CONCLUSION: Six pathogenic FLCN mutations were detected in patients from 10 families out of 15 families in the cohort. Therefore, genetic screening is necessary to validate the clinical diagnosis. The pathogenic mutations at FLCN affects the protein-protein interaction, which plays key roles in various metabolic pathways. Since, pathogenic mutations could not be detected in exonic regions of FLCN in 5 families, whole genome sequencing is necessary to detect all mutations at FLCN and/or any undescribed gene/s that may also be implicated in BHDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Orphanet journal of rare diseases - 17(2022), 1 vom: 27. Apr., Seite 176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ray, Anindita [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13023-022-02326-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340064056 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340064056 | ||
| 003 | DE-627 | ||
| 005 | 20231226004312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13023-022-02326-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340064056 | ||
| 035 | |a (NLM)35477461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ray, Anindita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic insight into Birt-Hogg-Dubé syndrome in Indian patients reveals novel mutations at FLCN |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is a rare monogenic condition mostly associated with germline mutations at FLCN. It is characterized by either one or more manifestations of primary spontaneous pneumothorax (PSP), skin fibrofolliculomas and renal carcinoma (chromophobe). Here, we comprehensively studied the mutational background of 31 clinically diagnosed BHDS patients and their 74 asymptomatic related members from 15 Indian families | ||
| 520 | |a RESULTS: Targeted amplicon next-generation sequencing (NGS) and Sanger sequencing of FLCN in patients and asymptomatic members revealed a total of 76 variants. Among these variants, six different types of pathogenic FLCN mutations were detected in 26 patients and some asymptomatic family members. Two of the variants were novel mutations: an 11-nucleotide deletion (c.1150_1160delGTCCAGTCAGC) and a splice acceptor mutation (c.1301-1G > A). Two variants were Clinvar reported pathogenic mutations: a stop-gain (c.634C > T) and a 4-nucleotide duplication (c.1329_1332dupAGCC). Two known variants were: hotspot deletion (c.1285delC) and a splice donor mutation (c.1300 + 1G > A). FLCN mutations could not be detected in patients and asymptomatic members from 5 families. All these mutations greatly affected the protein stability and FLCN-FNIP2 interaction as observed by molecular docking method. Family-based association study inferred pathogenic FLCN mutations are significantly associated with BHDS | ||
| 520 | |a CONCLUSION: Six pathogenic FLCN mutations were detected in patients from 10 families out of 15 families in the cohort. Therefore, genetic screening is necessary to validate the clinical diagnosis. The pathogenic mutations at FLCN affects the protein-protein interaction, which plays key roles in various metabolic pathways. Since, pathogenic mutations could not be detected in exonic regions of FLCN in 5 families, whole genome sequencing is necessary to detect all mutations at FLCN and/or any undescribed gene/s that may also be implicated in BHDS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BHDS | |
| 650 | 4 | |a FLCN mutations | |
| 650 | 4 | |a Family-based association | |
| 650 | 4 | |a Indian patients | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Primary spontaneous pneumothorax | |
| 650 | 7 | |a FLCN protein, human |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 700 | 1 | |a Chattopadhyay, Esita |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Bera, Arnab |e verfasserin |4 aut | |
| 700 | 1 | |a Sarma, Mridul |e verfasserin |4 aut | |
| 700 | 1 | |a Munot, Mahavir |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Unnati |e verfasserin |4 aut | |
| 700 | 1 | |a Rajan, Sujeet |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhudesai, Pralhad |e verfasserin |4 aut | |
| 700 | 1 | |a Prakash, Ashish K |e verfasserin |4 aut | |
| 700 | 1 | |a Roy Chowdhury, Sushmita |e verfasserin |4 aut | |
| 700 | 1 | |a Bhowmick, Niladri |e verfasserin |4 aut | |
| 700 | 1 | |a Dhar, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Udwadia, Zarir F |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Atin |e verfasserin |4 aut | |
| 700 | 1 | |a Mitra, Subhra |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Jyotsna M |e verfasserin |4 aut | |
| 700 | 1 | |a Maitra, Arindam |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Bidyut |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orphanet journal of rare diseases |d 2006 |g 17(2022), 1 vom: 27. Apr., Seite 176 |w (DE-627)NLM163016410 |x 1750-1172 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:1 |g day:27 |g month:04 |g pages:176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13023-022-02326-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 1 |b 27 |c 04 |h 176 | ||